Management Pharmaceutical manufacturing Pharmaceutical products 
European Pharmaceutical Review
APRIL 10, 2025
This poses a significant challenge for pharmaceutical manufacturers, not least because of the technical challenges related to operations, supply chain and the environment. This article explores the potential impact of the proposal and considers how manufacturers can ensure the safety and reliability of their products.
European Pharmaceutical Review
DECEMBER 4, 2023
However, the knowledge generated using a PAT framework can help to seamlessly transfer these insights to pilot testing and manufacturing operations. The result is efficient, cost-effective and high-quality (bio)pharmaceutical production. Enter the era of benchtop NMR solutions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
SEPTEMBER 29, 2022
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.
eMediWrite
JULY 13, 2023
From the examination of raw materials through the release of the finished packaged product, Quality Control Authorities like Central Drugs Standard Control Organisation in India established under the Drugs & Cosmetics Act, 1940. They play a crucial role in assuring the efficacy and safety of products given to patients.
pharmaphorum
NOVEMBER 24, 2022
However, with cleanrooms-on-demand representing a feasible and accessible opportunity for those across pharmaceutical manufacturing, what are the key challenges in adoption and how can we expect the industry to overcome them to reap the rewards on offer? But with a single dedicated cleanroom environment costing around $2.5
PM360
JANUARY 24, 2025
Applying AI to GVDs Amassing comprehensive productand market-related data, GVDs demonstrate the value of a pharmaceutical product to various stakeholders, including payers, healthcare providers, and regulatory bodies. It leveraged experts input at key points in the process, to assess and validate the work.
European Pharmaceutical Review
JULY 25, 2022
.” These products are disguised as legitimate branded medicines and it can be difficult for those across the supply chain, as well as patients, to detect counterfeit products from authentic originals. There is also the challenge of falsified medicines – the fake, unauthorised medical products that make their way into the market.
Expert insights. Personalized for you.
52 
Let's personalize your content